Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 5, Issue 8
April 27 2021
Issue Cover

Table of Contents

DRUG ADVANCES

Treating lymphoma is now a bit EZ-er
Clinical Trials & Observations
Ryan D. Morin,Sarah E. Arthur,Sarit Assouline
View Articletitled, Treating lymphoma is now a bit EZ-er
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies
Clinical Trials & Observations
Anand A. Patel,Kirk Cahill,Caner Saygin,Olatoyosi Odenike
View Articletitled, Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies

EXCEPTIONAL CASE REPORT

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency
Clinical Trials & Observations
Sandheeah Ramdeny,Asima Chaudhary,Austen Worth,Sara Ghorashian,Mary Slatter,Su Han Lum,Ajay Vora
View Articletitled, Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

STIMULUS REPORT

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
Clinical Trials & Observations
Flora Peyvandi,Spero Cataland,Marie Scully,Paul Coppo,Paul Knoebl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,Jessica Minkue Mi Edou,Hilde De Winter,Filip Callewaert
View Articletitled, Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
Supplemental data

SYSTEMATIC REVIEWS

Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis
Soravis Osataphan,Rushad Patell,Thita Chiasakul,Alok A. Khorana,Jeffrey I. Zwicker
View Articletitled, Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis
Supplemental data
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism
Parth Patel,Payal Patel,Meha Bhatt,Cody Braun,Housne Begum,Robby Nieuwlaat,Rasha Khatib,Carolina C. Martins,Yuan Zhang,Itziar Etxeandia-Ikobaltzeta,Jamie Varghese,Hani Alturkmani,Waled Bahaj,Mariam Baig,Rohan Kehar,Ahmad Mustafa,Rakesh Ponnapureddy,Anchal Sethi,Merrill Thomas,David Wooldridge,Wendy Lim,Shannon M. Bates,Eddy Lang,Grégoire Le Gal,Linda B. Haramati,Jeffrey Kline,Marc Righini,Wojtek Wiercioch,Holger Schünemann,Reem A. Mustafa
View Articletitled, Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis
Clinical Trials & Observations
Surbhi Sidana,Surendra Dasari,Taxiarchis V. Kourelis,Angela Dispenzieri,David L. Murray,Rebecca L. King,Ellen D. McPhail,Marina Ramirez-Alvarado,Shaji K. Kumar,Morie A. Gertz
View Articletitled, IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis
Supplemental data
Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis
Clinical Trials & Observations
Hyehyun Jeong,Hyungwoo Cho,Hyeyeong Kim,Heejung Chae,Jung-Bok Lee,Kyoungmin Lee,Shin Kim,Sang-wook Lee,Jin-Sook Ryu,Kyung Won Kim,Eun Jin Chae,Jooryung Huh,Chan-Sik Park,Dok Hyun Yoon,Cheolwon Suh
View Articletitled, Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis
Supplemental data
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
Clinical Trials & Observations
Donald L. Patrick,Annette Powers,Monika Parisi Jun,Yeonhee Kim,Jacob Garcia,Christine Dehner,David G. Maloney
View Articletitled, Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
Clinical Trials & Observations
Isabelle A. van Zeventer,Jonas B. Salzbrunn,Aniek O. de Graaf,Bert A. van der Reijden,H. Marike Boezen,Judith M. Vonk,Pim van der Harst,Jan Jacob Schuringa,Joop H. Jansen,Gerwin Huls
View Articletitled, Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse
Clinical Trials & Observations
Sophia Faude,Jane Wei,Kavitha Muralidharan,Xiaoming Xu,Gerald Wertheim,Michele Paessler,Vijay G. Bhoj,Stephan A. Grupp,Shannon L. Maude,Susan R. Rheingold,Vinodh Pillai
View Articletitled, Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse
Supplemental data

LYMPHOID NEOPLASIA

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
Cédric Ménard,Delphine Rossille,Joelle Dulong,Tien-Tuan Nguyen,Ilenia Papa,Maelle Latour,Nadège Bescher,Isabelle Bezier,Myriam Chouteau,Thierry Fest,Roch Houot,Franck Morschhauser,Karin Tarte
View Articletitled, Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
Supplemental data
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Hilma J. van der Horst,Anne T. Gelderloos,Martine E. D. Chamuleau,Esther C. W. Breij,Sonja Zweegman,Inger S. Nijhof,Marije B. Overdijk,Tuna Mutis
View Articletitled, Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Supplemental data
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Christie P. M. Verkleij,Marloes E. C. Broekmans,Mark van Duin,Kristine A. Frerichs,Rowan Kuiper,A. Vera de Jonge,Martin Kaiser,Gareth Morgan,Amy Axel,Rengasamy Boominathan,Jocelyn Sendecki,Amy Wong,Raluca I. Verona,Pieter Sonneveld,Sonja Zweegman,Homer C. Adams, III,Tuna Mutis,Niels W. C. J. van de Donk
View Articletitled, Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Supplemental data
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Clinical Trials & Observations
Toby A. Eyre,William Wilson,Amy A. Kirkwood,Julia Wolf,Catherine Hildyard,Hannah Plaschkes,John Griffith,Paul Fields,Arief Gunawan,Rebecca Oliver,Stephen Booth,Jaimal Kothari,Christopher P. Fox,Nicolas Martinez-Calle,Andrew McMillan,Mark Bishton,Graham P. Collins,Chris S. R. Hatton
View Articletitled, Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Supplemental data

MYELOID NEOPLASIA

Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis
Kaitlyn M. Dykstra,Hannah R. S. Fay,Ashish C. Massey,Neng Yang,Matthew Johnson,Scott Portwood,Monica L. Guzman,Eunice S. Wang
View Articletitled, Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis
Supplemental data
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs
Clinical Trials & Observations
Lucia Masarova,Courtney D. DiNardo,Prithviraj Bose,Naveen Pemmaraju,Naval G. Daver,Tapan M. Kadia,Helen T. Chifotides,Lingsha Zhou,Gautam Borthakur,Zeev Estrov,Marina Konopleva,Srdan Verstovsek
View Articletitled, Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs
Supplemental data
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Clinical Trials & Observations
Curtis A. Lachowiez,Sanam Loghavi,Ken Furudate,Guillermo Montalban-Bravo,Abhishek Maiti,Tapan Kadia,Naval Daver,Gautam Borthakur,Naveen Pemmaraju,Koji Sasaki,Yesid Alvarado,Musa Yilmaz,Nicholas J. Short,Kelly Chien,Maro Ohanian,Sherry Pierce,Keyur P. Patel,Elias Jabbour,Farhad Ravandi,Hagop M. Kantarjian,Guillermo Garcia-Manero,Koichi Takahashi,Marina Y. Konopleva,Courtney D. DiNardo
View Articletitled, Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Supplemental data
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
Manjola Balliu,Laura Calabresi,Niccolò Bartalucci,Simone Romagnoli,Laura Maggi,Rossella Manfredini,Matteo Lulli,Paola Guglielmelli,Alessandro Maria Vannucchi
View Articletitled, Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, <em>CALR</em>-mutated MPNs
Supplemental data
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Grace A. Ward,Kathy L. McGraw,Farnoosh Abbas-Aghababazadeh,Benjamin S. Meyer,Amy F. McLemore,Nicole D. Vincelette,Nghi B. Lam,Amy L. Aldrich,Najla H. Al Ali,Eric Padron,Javier Pinilla-Ibarz,Erico Masala,Valeria Santini,Olivier Kosmider,Michaela Fontenay,Pierre Fenaux,Joseph Johnson,Brooke L. Fridley,Alan F. List
View Articletitled, Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Supplemental data

THROMBOSIS AND HEMOSTASIS

Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD
Clinical Trials & Observations
Brandi Dupervil,Karon Abe,Sarah H. O’Brien,Meredith Oakley,Roshni Kulkarni,Courtney D. Thornburg,Vanessa R. Byams,J. Michael Soucie,for the US Hemophilia Treatment Center Network
View Articletitled, Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD

TRANSPLANTATION

Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis
Christine S. Higham,Griffin Collins,Kristin A. Shimano,Alexis Melton,Sandhya Kharbanda,Lena E. Winestone,James N. Huang,Jasmeen Dara,Janel R. Long-Boyle,Christopher C. Dvorak
View Articletitled, Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis
Supplemental data

RESEARCH LETTERS

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?
Clinical Trials & Observations
Chloé Prod’homme,Licia Touzet,Magali Pierrat,Luc Chevalier,Helene Lesaffre,Celine Berthon,Valerie Coiteux,Sarah Barbieux,David Beauvais,Loïc Bauschert,Marie De Charette,Laure Goursaud,Salomon Manier,Thierry Facon
View Articletitled, Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients
Clinical Trials & Observations
Marissa Li,Moritz Binder,Terra Lasho,Alejandro Ferrer,Naseema Gangat,Aref Al-Kali,Abhishek Mangaonkar,Michelle Elliott,Mark Litzow,William Hogan,Animesh Pardanani,Alexandra Wolanskyj-Spinner,Matthew Howard,Rebecca L. King,Mithun Shah,Hassan Alkhateeb,Kebede Begna,Ayalew Tefferi,Christy Finke,Jennifer Oliveira,Rhett Ketterling,Horatiu Olteanu,Mrinal M. Patnaik
View Articletitled, Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients
Supplemental data
A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML
Clinical Trials & Observations
Emily F. Mason,Olga Pozdnyakova,Mikhail Roshal,Amir T. Fathi,Eytan M. Stein,P. Brent Ferrell,Aaron C. Shaver,Mark Frattini,Hongfang Wang,Lei Hua,Jimmy Mu,Sung Choe,Rengyi Xu,Caroline Almon,Michael Cooper,Richard M. Stone,Robert P. Hasserjian,Michael R. Savona
View Articletitled, A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML
Supplemental data

COMMENTARY

13q12.2 deletions and FLT3 overexpression in acute leukemias
Caroline Pires Poubel,Mariana Boroni,Mariana Emerenciano
View Articletitled, 13q12.2 deletions and <em>FLT3</em> overexpression in acute leukemias
All Issues

Advertisement

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Race and ethnicity reporting and representation in hemophilia clinical trials

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement